INIBIC-VC - Artigos: Envíos recentes
Mostrando ítems 11-15 de 37
-
Effectiveness and Safety of Sofosbuvir/Velpatasvir ± Ribavirin vs Glecaprevir/Pibrentasvir in Genotype 3 Hepatitis C Virus Infected Patients
(BMJ Publishing Group, 2020-02-07)[Abstract] Objectives. Sofosbuvir/velpatasvir±ribavirin (SOF/VEL±RBV) and glecaprevir/pibrentasvir (GLE/PIB) are the drug combinations of choice for treating individuals with genotype 3 hepatitis C virus (G3-HCV) infection. ... -
Deep-Sequencing Reveals Broad Subtype-Specific HCV Resistance Mutations Associated with Treatment Failure
(Elsevier, 2019-12-16)[Abstract] A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was ... -
Effectiveness and Safety of Direct‐Acting Antivirals in Hepatitis C Infected Patients With Mental Disorders: Results in Real Clinical Practice
(Willey Online Library, 2020-03-17)[Abstract] The aim of this study is to analyze the effectiveness and safety of direct‐acting antivirals (DAAs) in psychiatric patients with chronic hepatitis C (CHC). Secondary objectives included adherence and drug‐drug ... -
Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain
(Frontiers, 2019-08-03)[Abstract] In Western Europe, the HIV-1 epidemic among men who have sex with men (MSM) is dominated by subtype B. However, recently, other genetic forms have been reported to circulate in this population, as evidenced ... -
Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
(Plos ONE, 2019-06-03)[Abstract] BACKGROUND: Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular ...